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Abstract
Background: The role of B Lymphocyte Stimulator (BLyS) in the survival of malignant B cells and the maintenance
of normal B cell development and homeostasis has been intensively studied in the literature. However, the
influence of BLyS on breast cancer progression remains unclear. The study aimed to investigate the effect of
hypoxia on BLyS regulation, cell migratory response to BLyS and the possible molecular mechanisms.
Methods: In this study, we examined the role of BLyS in the migration of human breast cancer cells by transwell
assay. We also explored whether BLyS and its receptors expressed in human breast cancer cell lines by
immunofluorescence and Western Blotting. Then we detected the expression level of BLyS in both normoxic and
hypoxic conditions by real time-PCR and Western Blotting. Pathways involved were confirmed by Western Blotting,
immunofluorescence, transwell assay and luciferase assay.
Results: According to our study, the expression level of BlyS was increased in human breast cancer cell lines in
hypoxic conditions. Up-regulation of this protein led to activation and nuclear translocation of NF-kappa B p65. We
also found that the number of migrated cells was increased in the presence of BLyS and inhibition of
phosphorylation of Akt attenuated the enhanced migratory response.
Conclusions: It suggested that better understanding of BLyS, an immunopotentiator, may offer a potential
therapeutic target for the treatment of human breast cancers. In addition, BLyS promoted breast cancer cells
migration, underscoring the necessity of appropriate applications of immunopotentiators to cancer treatment.
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Background
B Lymphocyte Stimulator (BLyS), a key member of the
tumor necrosis factor superfamily, binds to three recep-
tors: B-cell maturation antigen (BCMA), transmembrane
activator and CAML interactor (TACI), and B cell-acti-
vating factor receptor (BAFF-R). BLyS promotes survival
of splenic immature transitional and mature B cells [1].
Over-expression of BLyS has been associated with mul-
tiple myeloma (MM) [2], Systemic lupus erythematosus
(SLE) [3] and B cell lymphoma [4]. It has also been
reported that this ligand/receptor dyad plays a critical
role in the growth and survival of malignant plasma
cells and B cells [5]. Recent studies in ductal breast can-
cer patients have suggested a role of BLyS in the devel-
opment of breast cancer. But its molecular mechanisms
remain to be elucidated [6].
Hypoxia plays a significant role in the pathogenesis of
heart disease, cancer, neuron death, etc. [7]. Inflamma-
tory factors have been shown to be transcriptional regu-
lated by hypoxia induced factor-1a (HIF-1a)o rN F -
kappa B in hypoxic conditions [8]. The expression of
BLyS is up-regulated by hypoxia, while the mechanism
is still uncertain. We hypothesized that HIF-1a or NF-
kappa B pathway might be responsible for the up-regu-
lation. In addition, the inflammatory factors such as
TNF-a,I L - 1 a lead to increased cancer cell migration
[9]. Therefore, the human breast cancer cell migration
in response to BLyS and possible molecular mechanisms
were explored in this study.
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Cell line and cell culture
Breast cancer cell lines MDA-MB-435, MDA-MB-231
and MDA-MB-468 and B cell line Ramos were pur-
chased from Cell Bank of Institute of Biochemistry and
Cell Biology, Chinese Academy of Sciences (Shanghai,
China). MDA-MB-435 cells and Ramos cells were cul-
tured in Dulbecco’s Modified Eagle’s Medium (Gibco,
Grand Island, NY) and MDA-MB-231 cells and MDA-
MB-468 cells were cultured in L-15 (Gibco, Grand
Island, NY), containing 10% fetal bovine serum (Gibco,
Grand Island, NY). The cells were used from three to
six passages.
Materials
Anti-human BLyS and anti-human TACI antibodies
were obtained from R&D Systems (Minneapolis, MN).
Anti-human BAFF-R and anti-human BCMA antibodies
were purchased from Abcam Inc (Cambridge, MA).
Anti-Lamin B, anti-NF-kappa B p65 antibodies and don-
key anti-goat secondary antibodies were obtained from
Santa-Cruz (Santa Cruz, CA). Anti-Akt, anti-p-Akt (Ser
473), anti-p38 MAPK, anti-p-p38 MAPK (Tyr 182),
anti-HIF-1a antibodies and goat anti-rabbit secondary
antibodies were obtained from Cell Signaling (Beverly,
MA) Anti-b-actin antibody was obtained from Sigma
(St. Louis, MO). Goat anti-mouse peroxidase-conjugated
antibody was from Sigma (St. Louis, MO). RevertAid™
first strand cDNA Synthesis Kit, TurboFect™ in vitro
transfection reagent and restriction enzymes Kpn I and
Xho I were purchased from Fermentas (Shenzhen,
China), Dual-luciferase assay system, pGL3-basic (pro-
moterless) luciferase vector and pRL-SV40 plasmid were
obtained from Promega (San Francisco, California,
USA). API-1, SB 202190, PX 12 and Caffeic acid phe-
nethyl ester (CAPE) were from Tocris (Bristol, UK).
Recombinant human BAFF was purchased from R&D
system (Minneapolis, MN). SYBR Premix Ex Taq II and
pMD
® 18-T Vector were purchased from TAKARA
(Dalian, China). DNA purification kit, QIAprep spin
miniprep kit and QIAquick gel extraction kit were pur-
chased from Qiagen (Shanghai, China).
Migration assay
Cell migration assay were performed in a double cham-
ber transwell (Corning) with polycarbonate membranes
(8.0 μmp o r es i z e ) .8×1 0
4 cells were added to the
upper chamber, treated with or without specific antago-
nists. Different concentrations of BLyS were added to
the lower chamber. 1% FBS was used as a negative con-
trol. After incubation at 37 for 8 h in hypoxic or nor-
moxic conditions, migrated cells were stained and
counted in five randomly selected fields.
Quantitative real-time PCR
Total RNA was extracted using a Trizol reagent (Invi-
trogen Corporation, Grand Island, NY, USA) and was
reversed to cDNA using RevertAid™ first strand cDNA
Synthesis Kit according to the manufacturer’si n s t r u c -
tions. All primers were synthesized by Sangon Biotech
(Shanghai, China) or TAKARA (Dalian, China). The pri-
mers used in Q-PCR are listed as follow: BLyS (Gen-
Bank, NM_006573.4) 5’- CGT GCC GTT CAG GGT
CCA G-3’ (forward) and 5’-TCG AAA CAA AGT CAC
CAG ACT CAA T-3’ (reverse); b-actin (GenBank,
AF035119) 5’-CTC CTC CTG AGC GCA AGT ACT C-
3’ (forward) and 5’-CGG ACT CGT CAT ACT CCT
GCT-3’ (reverse). The gene levels in the resultant
cDNAs were examined using the detection system
(TAKARA) with SYBR-green as fluorescent dye enabling
real time detection of PCR products according to the
manufacturer’s protocol. The relative expression levels
of the genes were determined against b-actin levels in
the samples.
Western blotting analysis
Total cell lysates were prepared in RIPA buffer supple-
mented with protease inhibitors. The proteins were frac-
tionated by 8%-12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
electroblotted onto nitrocellulose membrane (Bio-Rad).
The membranes were probed with primary antibodies
and then probed with relative secondary antibody. b-
actin was used as a loading control.
Immunofluorescence
For BLyS and its three receptors staining in cells, MDA-
MB-435, MDA-MB-231, MDA-MB-468 cells and Ramos
cells were seeded on coverslips and cultured in 5% CO2
incubator. At 12 h after subculture, the plate with
Ramos cells was centrifuged at 1, 000 rpm for 10 min
and all the cells were fixed in 4% paraformadehyde for
10 min, washed and incubated with anti-BLyS antibody,
anti-BAFF-R antibody, anti-BCMA antibody and anti-
TACI antibody (1:100 dilution in 1% BSA-PBS). The
cells were then incubated with relative FITC-conjugated
secondary antibody (1:1000 dilution in 1% BSA-PBS) for
1 h at room temperature and with Hoechst 33342 for
30 minutes. The processed cells were mounted and
fluorescence microscopy images were taken from five
random fields in each slide using an inverted micro-
scope (Olympus IX 71, Japan).
Plasmid construction, transient transfection and luciferase
assays
pGL3-Basic luciferase vector, a plasmid of luciferase-
reporter for human BLyS promoter (GenBank,
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reporter constructs. DNA was extracted from MDA-
MB-435 cells. BLyS promoter was amplified by PCR
using following primers: 5’- GCG GTA CCA AGC CTG
GGT CTG GAG TTC T-3’ (forward) and 5’-G C CT C G
AGC CTT TCT GCC TTT CTG CAT C-3’ (reserve).
Cloned fragments were recovered and ligated into
pGL3-basic luciferase vector. DNA transfectants were
prepared using QIAprep spin miniprep kit. Cells were
cultured in 24-well plates to 70-80% of confluence, and
then transfected with 1 μg of pGL3-Basic/BP or pGL3-
Basic. Plasmid pRL-SV40 Renilla luciferase reporter (20
ng) was used as internal control. Supernatant was
removed after 24 h and the cells were subsequently trea-
ted with CAPE for 12 h. Cell extracts were prepared and
analyzed for luciferase activity using Dual-luciferase
reporter assay system. Luciferase activity was expressed
as relative luciferase activity (RLA).
Statistical analyses
The results are presented as the mean ± SD where
applicable. Data were analyzed using GraphPad Prism
5.0 and the Student’s t-test to determine the level of sig-
nificance. Statistical difference was accepted at p < 0.05.
(GraphPad Prism 5.0 was used to perform statistical
analysis.)
Results and discussion
Expressions of BLyS, TACI, BCMA and BAFF-R in human
breast cancer cell lines
The expression of BLyS has been detected in monocytes,
macrophages and T cells. The three receptors are
mainly in B cells, T cells and several kinds of malignant
cells [10]. It is reported that both BLyS and its receptors
are present in Ramos cells [11,12]. As shown in Figure
1A, BLyS and the receptor proteins were present in
MDA-MB-435, MDA-MB-231 and MDA-MB-468 cells
by immunofluorescence and Western Blotting. Ramos
cells were used as positive control. However, BAFF-R
chiefly accumulated in the nucleus of MDA-MB-435
and MDA-MB-231 cells, indicating that BAFF-R may
act as a transcription regulator of certain target genes
including BLyS, CD154 and so on. It is reported that
BAFF-R is capable of functioning both as a growth/sur-
vival cell membrane receptor, as well as a transcription
factor or cofactor to promote B-cell survival and prolif-
eration [13]. Further studies are necessary for confirm-
ing this hypothesis.
A ss h o w ni nF i g u r e1 B ,t h em R N Al e v e lo fB L y Si n
MDA-MB-435 cell was dramatically increased in
hypoxic conditions based on Q-PCR assay. In Figure 1C,
protein level of BLyS was significantly elevated in
hypoxic conditions for 3 h to 6 h. On the basis of Wes-
tern Blotting data in MDA-MB-435 cells, we observed
that BLyS was present not only as a dimer (~32 kDa) in
plasma membrane and cytoplasm, but also as a trimer
(~52 kDa) in supernatant. Both of the BLyS signals (~32
k D aa n d~ 5 2k D a )w e r es t r o n g l ye n h a n c e db yt h el o w
oxygen tension.
Migration of human breast cancer cells in the presence of
BLyS
We determine breast cancer cells migration when trea-
ted with BLyS in both normoxic and hypoxic conditions.
As seen in Figure 2, BLyS significantly enhanced the
migration of MDA-MB-435, MDA-MB-231 and MDA-
MB-468 cells in vitro compared with the negative con-
trol. The responses of the three cell lines to BLyS were
different. BLyS treatment caused dose-dependent
response in MDA-MB-435 and MDA-MB-468. How-
ever, no difference was found between the migration of
MDA-MB-231 when treated with 10 ng/ml of BLyS
compared to 0.1 ng/ml or 1 ng/ml of BLyS.
Role of p65 activation in BLyS up-regulation
NF-kappa B is critical for the regulation of apoptosis,
viral replication, tumorigenesis, inflammation and var-
ious autoimmune diseases. It is activated by a variety of
stimuli such as hypoxia [14]. We also explored the pos-
sible involvement of HIF-1a which can be modulated by
low oxygen tension in cells and tissues. HIF-1a leads to
the transcriptional induction of a series of genes that
participates in angiogenesis, iron metabolism, and glu-
cose metabolism [15].
HIF-1a was up-regulated and p65 was translocated by
hypoxia (Figure 3A). CAPE, a NF-kappa B antagonist,
specifically inhibits NF-kappa B activation and PX 12
attenuates expressions of HIF-1a and VEGF. Decreased
activation of p65 resulted in BLyS downregulation in
MDA-MB-435 cells (Figure 3B). MDA-MB-435 cells
were transfected with pGL3-Basic/BP plasmid and then
treated with CAPE or PX 12 for 12 h. The RLA data
suggested that CAPE rather than PX-12 decreased the
BLyS promoter activity significantly (Figure 3C). Immu-
nofluorescence showed that p65 could be activated by
hypoxia and CAPE was against the activation. It also
showed that CAPE blocked expression of BLyS in
hypoxic conditions (Figure 3D). The preceding results
showed that translocation of p65, rather than accumula-
tion of HIF-1a, was responsible for BLyS up-regulation.
Activation of akt protein involved in BLyS-enhanced cell
migration
We have found that BLyS stimulated human breast can-
cer cell migration. Activation of Akt and p38 MAPK
pathways might contribute to BLyS-enhanced cell
migration. SB 202190 is a p38 MAPK antagonist and
API-1 is an Akt/protein kinase B (PKB) antagonist.
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to BLyS or 2% FBS was blocked by SB 202190 and/or
API-1 (Figure 4A). MDA-MB-435 cells were treated
with BLyS for 4 h, which led to the maximal phosphory-
lation levels of Akt protein (Figure 4B). As shown in
Figure 4C, BLyS-induced phosphorylations of Akt could
be abrogated by the specific inhibitors. But phosphoryla-
tion level of p38 MAPK induced by BLyS did not
increase significantly as compared to the control. It
suggested that inhibition by SB 202190 could be
through another mechanism and BLyS-independent. In
short, BLyS probably promoted breast cancer cell migra-
tion via Akt pathways.
Discussion
We initially demonstrated that hypoxia modulated the
expressions of BLyS and its receptors in human breast
cancer cell lines. Our data also indicated enhanced
Figure 1 Expressions of BLyS, TACI, BCMA and BAFF-R in human breast cancer cell lines. (A) BLyS and its three receptors in human breast
cancer cell lines MDA-MB-435, MDA-MB-231, MDA-MB-468 and B cell line Ramos by immunofluorescence (original magnification 200 ×) and
Western Blotting. (B) The mRNA level of BLyS in the three cell lines were detected by real-time PCR under hypoxia for different time points. Data
were means of triplicate samples with ± SD; vs normoxia, *, P < 0.05; **, P < 0.01; ***, P < 0.001. (C) BLyS protein level in MDA-MB-435 cells by
Western Blotting analysis.
Zhu et al. Journal of Experimental & Clinical Cancer Research 2012, 31:31
http://www.jeccr.com/content/31/1/31
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chamber. 2% FBS and 1% FBS added in the lower chamber were used as positive chemoattractant and negative chemoattractant respectively.
(A) MDA-MB-435. (B) MDA-MB-231. (C) MDA-MB-468. Average numbers of cells migrating in five randomly selected fields were counted after 8 h
(original magnification 200 ×). Data are means of triplicate samples with ± SD; *, P < 0.05, **, P < 0.01, ***, P < 0.001, vs 1% FBS under normoxia.
#, P < 0.05, ##, P < 0.01, ###, P < 0.001, vs 1% FBS under hypoxia.
Figure 3 Role of p65 activation in BLyS up-regulation.( A) HIF-1a and p65 protein levels in MDA-MB-435 in hypoxic conditions for different
time points by Western Blotting. (B) CAPE(50 μM)and PX 12 (10 μM) were used to determine the roles of p65 and HIF-1a in the regulation of
BLyS expression by Western Blotting. The cells were treated with or without inhibitor in normoxic or hypoxic conditions for 6 h. (C) Effects of
CAPE(50 μM)and PX 12 (10 μM) on BLyS promoter activity. Data were average luciferase activities of three independent transfections with ± SD.
*, P < 0.05, vs pGL3-Basic/BP. (D) Localization of p65 protein and expression level of BLyS by immunofluorescence. MDA-MB-435 cells were
challenged with CAPE (50 μM) for 6 h (original magnification 200 ×).
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vitro. BlyS, an immunopotentiator, might be a potential
therapeutic target in breast cancer treatment base on
this study, but care should be taken for using immuno-
potentiator in cancer treatment. Cancer tissues consist
of large amounts of mesenchymal cells including fibro-
blasts, endothelial cells, adipocytes as well as inflamma-
tory cells. As we know, inflammatory cells are a major
source of BLyS, suggesting that BLyS may act as a con-
nection between inflammatory cells and cancer cells.
Furthermore, growing evidences show that cancer can
evolve from chronic inflammation [16]. Inflammation
often accompanies cancer and recruits inflammatory
cells which release plenty of inflammatory factors [17].
In addition, cancer-associated fibroblasts mediate can-
cer-enhancing inflammation [18]. Despite the relation-
ship between inflammation and cancer is still poorly
understood, it is believed that inflammatory cells are not
the “street sweeper” in cancer tissues all along, but may
trigger cancer progression [19]. Many other processes,
such as EMT, are involved in the transition from inflam-
mation to cancer [20]. It is prospected that an advanced
breast cancer treatment could be developed if this field
is much deeply explored.
Previous study reported that NF-kappa B played a key
role in the transition from inflammation to cancer [21].
Cancer with NF-kappa B activity usually shows increased
resistance to chemotherapy [22]. Furthermore, NF-kappa
B is required for the expressions of many inflammatory
genes [23]. Curcumin inhibited BLyS expression by
decreasing the nuclear translocation of p65 in B lympho-
cyte cell lines [10]. Regarding HIF-1a, its protein level is
extremely low in normoxic conditions. HIF-1a protein
accumulates under hypoxia and regulates the target
genes [8]. Interestingly, NF-kappa B also activates angio-
genesis encoding genes HIF-1a and VEGF [24,25]. Mobi-
lity of cancer cells and cytokines productions are altered
by hypoxia. All of these alterations will finally lead to
angiogenesis, matrix degradation and metastasis in can-
cer. Cancer cells adapt to hypoxia for survival [26].
It is reported that BLyS suppresses the progression of
several kinds of tumors and plays an important role in
the development of immune system diseases [27]. How-
ever, our results showed an enhanced migratory in
response to BLyS. Several reports support the critical
roles of Akt and p38 MAPK in cancer cell survival,
migration, apoptosis and anti-apoptosis [28,29]. Previous
research indicated that BLyS led to rapid phosphoryla-
tions of Akt in B cells [30]. Our studies suggested that
phosphorylations of Akt were essential for BLyS-
enhanced cell migration in vitro.
Conclusion
In conclusion, the results found that BLyS caused the
enhanced migration of human breast cancer cells, while
BLyS was up-regulated by hypoxia. However, further
studies are required to confirm the mechanisms of BLyS
action and reveal the relationship between inflammation
and breast cancer progression.
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